DE69739478D1 - Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung - Google Patents

Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung

Info

Publication number
DE69739478D1
DE69739478D1 DE69739478T DE69739478T DE69739478D1 DE 69739478 D1 DE69739478 D1 DE 69739478D1 DE 69739478 T DE69739478 T DE 69739478T DE 69739478 T DE69739478 T DE 69739478T DE 69739478 D1 DE69739478 D1 DE 69739478D1
Authority
DE
Germany
Prior art keywords
cadasil
therapeutic use
diagnostic methods
related gene
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739478T
Other languages
English (en)
Inventor
Elisabeth Tournier-Lasserve
Anne Joutel
Marie-Germaine Bousser
Jean-Francois Bach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9609733A external-priority patent/FR2751985B1/fr
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Assistance Publique Hopitaux de Paris APHP
Application granted granted Critical
Publication of DE69739478D1 publication Critical patent/DE69739478D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69739478T 1996-08-01 1997-07-31 Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung Expired - Lifetime DE69739478D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9609733A FR2751985B1 (fr) 1996-08-01 1996-08-01 Gene implique dans le cadasil, methode de diagnostic et application therapeutique
FR9704680A FR2751986B1 (fr) 1996-08-01 1997-04-16 Gene implique dans le cadasil, methode de diagnostic et application therapeutique
PCT/FR1997/001433 WO1998005775A1 (fr) 1996-08-01 1997-07-31 Gene implique dans le cadasil, methode de diagnostic et application therapeutique

Publications (1)

Publication Number Publication Date
DE69739478D1 true DE69739478D1 (de) 2009-08-13

Family

ID=26232895

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739478T Expired - Lifetime DE69739478D1 (de) 1996-08-01 1997-07-31 Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung

Country Status (9)

Country Link
US (3) US6537775B1 (de)
EP (1) EP0915973B1 (de)
JP (2) JP4463329B2 (de)
AT (1) ATE435281T1 (de)
CA (1) CA2262459C (de)
DE (1) DE69739478D1 (de)
ES (1) ES2328304T3 (de)
FR (1) FR2751986B1 (de)
WO (1) WO1998005775A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US8044259B2 (en) * 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
CA2457879A1 (en) * 2001-08-22 2003-03-06 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
WO2005111072A2 (en) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Notch-based fusion proteins and uses thereof
CN1763196B (zh) * 2004-09-13 2010-09-08 首都医科大学宣武医院 基因突变类型及基因测序方法
US7585968B2 (en) * 2005-03-28 2009-09-08 Isis Pharmaceuticals, Inc. Compositions and their uses directed to thymus and activation-regulated chemokine (TARC)
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007053577A2 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AU2006308847C1 (en) 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
JP2009539403A (ja) 2006-06-13 2009-11-19 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌を診断および処置するための組成物および方法
AU2007309229B8 (en) 2006-10-19 2013-05-09 Genentech, Inc. Anti-Notch3 agonist antibodies and their use in the treatment of Notch3-related diseases
TW200823293A (en) 2006-10-19 2008-06-01 Genentech Inc Novel anti-Notch3 antibodies and their use in the detection and diagnosis of disease
TWI419904B (zh) * 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
WO2009025867A2 (en) 2007-08-23 2009-02-26 The Trustees Of Columbia University In The City Of New York Compositions of humanized notch fusion proteins and methods of treatment
US7807630B2 (en) 2007-09-14 2010-10-05 Vanderbilt University Targeting of Notch3 receptor function for cancer therapy
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
AU2009283134B2 (en) 2008-08-22 2015-05-14 The Trustees Of Columbia University In The City Of New York Human Notch3 based fusion proteins as decoy inhibitors of Notch3 signaling
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
JP2012515547A (ja) * 2009-01-26 2012-07-12 アカデミス ズィーケンハイス レイデン ハー．オー．デー．エン． エルユーエムセー Ｎｏｔｃｈ３タンパク質発現および／またはｎｏｔｃｈ３のコード領域を調節するための手段および方法；ｃａｄａｓｉｌの処置におけるその組成物および使用
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
AU2011205316B2 (en) 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
WO2011140295A2 (en) * 2010-05-06 2011-11-10 President And Fellows Of Harvard College Modulators of notch receptor signaling and methods of use thereof
AR088048A1 (es) 2011-10-04 2014-05-07 Univ Columbia Señuelos notch1 humanos
CN104768579A (zh) 2012-10-23 2015-07-08 昂科梅德制药有限公司 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
TWI589590B (zh) 2012-11-07 2017-07-01 輝瑞股份有限公司 抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
EP2950885B1 (de) 2013-02-04 2018-11-21 Oncomed Pharmaceuticals, Inc. Verfahren und überwachung einer behandlung mit einem wnt-pfad-hemmer
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2018183219A2 (en) * 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Nucleic acid-based compositions and methods for treating small vessel diseases
US11453718B2 (en) 2017-03-27 2022-09-27 The Schepens Eye Research Institute, Inc. NOTCH3 agonist compositions and methods for treating small vessel diseases
US20200103419A1 (en) * 2017-03-27 2020-04-02 The Schepens Eye Research Institute, Inc. Blood biomarkers and diagnostic methods for small vessel diseases
EP4347634A1 (de) * 2021-06-02 2024-04-10 Regeneron Pharmaceuticals, Inc. Behandlung von zerebrovaskulären erkrankungen mit neurogenen locus notch homolog protein 3 (notch3) mitteln

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116628A1 (en) * 1994-02-28 1995-08-29 Anne Marie Gisele Joutel Method for the diagnosis of cadasil
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique

Also Published As

Publication number Publication date
CA2262459C (fr) 2013-03-26
WO1998005775A1 (fr) 1998-02-12
JP2010042012A (ja) 2010-02-25
US6995257B1 (en) 2006-02-07
EP0915973B1 (de) 2009-07-01
US20030186290A1 (en) 2003-10-02
ATE435281T1 (de) 2009-07-15
JP2001500366A (ja) 2001-01-16
US6537775B1 (en) 2003-03-25
US7138234B2 (en) 2006-11-21
JP4463329B2 (ja) 2010-05-19
EP0915973A1 (de) 1999-05-19
ES2328304T3 (es) 2009-11-11
FR2751986A1 (fr) 1998-02-06
FR2751986B1 (fr) 1998-12-31
CA2262459A1 (fr) 1998-02-12

Similar Documents

Publication Publication Date Title
DE69739478D1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
DK0914144T3 (da) Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE269402T1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
ATE385806T1 (de) Fusionsproteine
TR200700740T2 (tr) Nogo genlerinin nükleotid ve protein dizileri ve bunlar bazında yöntemler
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
DE3856180D1 (de) Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
NO20055309L (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
ATE455185T1 (de) Atypische protein-kinase-c-isoformen bei erkrankungen des nervensystems und krebs
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE602004007924D1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
DE69910425D1 (de) Neue therapeutische verwendung von nicergoline
PT782630E (pt) Gene da doenca poliquistica do rim
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
FI963170A (fi) Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i
HUP0202166A2 (hu) Bakteriális patogén gének globális szabályzói: bakteriális autoindukálószer-inaktiváló fehérje, és alkalmazása betegség elleni rezisztenciát kiváltó, géntechnológiai módosításokra
DE60235996D1 (de) Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen
DE602005019540D1 (de) Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition